GlassScriptPhysician profile
Timothy Eugene Graham
NPI 1134162258
$90,342.06
in general payments reported to CMS, 2019-2025
57 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $13K · 2021: $10K · 2022: $1,744 · 2023: $3,642 · 2024: $11K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,829 · Food and Beverage: $7,456 · Travel and Lodging: $3,700 · Honoraria: $325 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $249 · Education: $93.99 · Entertainment: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,428.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,828.50 |
| Food and Beverage | $7,456.28 |
| Travel and Lodging | $3,700.45 |
| Honoraria | $325.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $249.26 |
| Education | $93.99 |
| Entertainment | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46,457.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $11,772.45 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $10,676.50 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $5,617.88 | 2020-2025 | |
| Ascendis Pharma Endocrinology INC | $4,737.81 | 2023-2025 | Yorvipath |
| Insulet Corporation | $2,256.17 | 2020-2025 | Omnipod |
| Eli Lilly and Company | $1,455.81 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $1,027.56 | 2022-2025 | |
| Amgen INC. | $592.34 | 2022-2025 | Evenity, Repatha, Prolia |
| Chiesi USA, INC. | $571.62 | 2024-2025 | Mycapssa, Myalept |
| Lilly USA, LLC | $557.24 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $523.19 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $509.94 | 2020-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $387.59 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Antares Pharma, INC. | $284.11 | 2021-2024 | Xyosted, Nocdurna, Tlando |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $263.72 | 2021-2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $257.92 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $253.42 | 2020-2024 | Farxiga |
| Corcept Therapeutics | $224.02 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.53 | 2021-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $155.33 | 2023-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $150.00 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $133.78 | 2021-2025 | |
| Amryt Pharma Holdings LTD | $133.34 | 2022-2023 | Mycapssa |
| Ascensia Diabetes Care US INC. | $125.51 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $104.83 | 2024-2025 | |
| Madrigal Pharmaceuticals | $94.43 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $82.66 | 2022-2024 | Tirosint, Licart, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $67.15 | 2022-2025 | |
| Horizon Therapeutics Plc | $62.09 | 2023 | Tepezza, Procysbi |
| Boston Scientific Corporation | $49.71 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Amphastar Pharmaceuticals, INC. | $41.77 | 2024 | Baqsimi |
| Optos, INC. | $39.96 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Radius Health, INC. | $37.31 | 2024-2025 | Tymlos |
| Cequr Corporation | $35.47 | 2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $32.32 | 2020 | |
| Nevro Corp. | $31.99 | 2023 | Senza |
| Lifescan, INC. | $31.19 | 2021-2022 | |
| Mannkind Corporation | $30.12 | 2020-2021 | |
| Vistapharm, INC. | $23.46 | 2021 | |
| Kyowa Kirin, INC. | $23.10 | 2023 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $22.45 | 2024 | Evkeeza |
| Rhythm Pharmaceuticals, INC. | $21.64 | 2025 | Imcivree |
| Becton, Dickinson and Company | $19.77 | 2022 | |
| Halozyme INC | $19.32 | 2023 | |
| Pfizer INC. | $18.33 | 2025 | |
| Amneal Pharmaceuticals LLC | $15.31 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.29 | 2025 | Azmiro |
| Smith+Nephew, INC. | $14.11 | 2025 | Grafix Pl |
| Inspire Medical Systems, INC. | $13.72 | 2025 | Inspire |
| Ultragenyx Pharmaceutical INC. | $13.49 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.33 | 2022 | |
| Avion Pharmaceuticals | $13.23 | 2022 | |
| Clarus Therapeutics INC. | $13.16 | 2021 | |
| Zealand Pharma US, INC. | $11.04 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$48,742.55 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.